Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 19
HOS-086292 · Präparat HOS-083284
Serum concentrations may be increased due to CYP3A and P-gp inhibition by
Riociguat
ritonavir. The co-administration of riociguat with ritonavir is not recommended (see
section 4.4 and refer to riociguat SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 70524e0e108a183d2d1d21b8c777cf5a2204c4e0b83d06e364f3d706a46e103c · Zeichen 40781–41065 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-086465 · Präparat HOS-083284
Serum concentrations may be increased due to CYP3A and P-gp inhibition by ritonavir.
Riociguat
The co-administration of riociguat with ritonavir is not recommended (see section 4.4 and
refer to riociguat SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 611eae109733da8e2b8ed17cb6bef497821bf5af0b39cec9dfff51c0df3a8962 · Zeichen 41868–42160 im Abschnitt
Gegenanzeigen · Viagra
VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3–4
HOS-088776 · Präparat HOS-083727
3
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 514cc64ce37e263f485f6b2f45b7111a3d36cb54fd009b79d8c7cd281fe5cd15 · Zeichen 469–682 im Abschnitt
Gegenanzeigen · Viagra
VIAGRA 50 mg orodispersible tablets · Abschnitt 4.3 · PDF-Seite 17
HOS-088836 · Präparat HOS-083727
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 8f544c13b61bef2b6bc6eeae57ce7b53ff1b75095b32b53e2a06ade095001471 · Zeichen 413–623 im Abschnitt
Gegenanzeigen · Viagra
VIAGRA 50 mg orodispersible films · Abschnitt 4.3 · PDF-Seite 31
HOS-088887 · Präparat HOS-083727
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage abbea2eded8461c7f0476e1851671e3ba4ac296dfea68a7ea0ff323410b31eaf · Zeichen 413–623 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088798 · Präparat HOS-083727
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5
inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
sildenafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage fb207357e01f6963af8ef0ba3724a31dffe7034c79512e41a6f13722046d8352 · Zeichen 5051–5498 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 50 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 20–21
HOS-088855 · Präparat HOS-083727
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5
inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
sildenafil, is contraindicated (see section 4.3).
20
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) doxazosin (HOS-088800) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage b828f8947fcc03e3016c59c4b438ec2d0048266fb83b7e546a68a4e887ecc849 · Zeichen 5054–6570 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 50 mg orodispersible films · Abschnitt 4.5 · PDF-Seite 34
HOS-088905 · Präparat HOS-083727
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5
inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
sildenafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage fb207357e01f6963af8ef0ba3724a31dffe7034c79512e41a6f13722046d8352 · Zeichen 5052–5499 im Abschnitt
Wechselwirkungen · Ziagen
Ziagen 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-089991 · Präparat HOS-083963
6
Riociguat: In vitro, abacavir inhibits CYP1A1. Concomitant administration of a single dose of
riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine
(600 mg/50 mg/300 mg once daily) led to an approximately three-fold higher riociguat AUC(0-∞)
when compared to historical riociguat AUC(0-∞) reported in healthy subjects. Riociguat dose may
need to be reduced. Consult the riociguat prescribing information for dosing recommendations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) dolutegravir (HOS-089992) lamivudine (HOS-085829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:13:00Z · SHA-256 5ae0e9d13123c9bc32a3fb0e0e28b30666a7ec0ca822b9a0f255860ec60bcfbd · Passage 256365e27ff8599c98433115eefe5b98f341d5eb70b4973645496c1948daad94 · Zeichen 2040–2517 im Abschnitt
Wechselwirkungen · Ziagen
Ziagen 20 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 25
HOS-090029 · Präparat HOS-083963
Riociguat: In vitro, abacavir inhibits CYP1A1. Concomitant administration of a single dose of
riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine
(600 mg/50 mg/300 mg once daily) led to an approximately three-fold higher riociguat AUC(0-∞)
when compared to historical riociguat AUC(0-∞) reported in healthy subjects. Riociguat dose may
need to be reduced. Consult the riociguat prescribing information for dosing recommendations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) dolutegravir (HOS-089992) lamivudine (HOS-085829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:13:00Z · SHA-256 5ae0e9d13123c9bc32a3fb0e0e28b30666a7ec0ca822b9a0f255860ec60bcfbd · Passage ea8fcaebe617386f58b28436deabd35b752edd5612b1bc5946d8d2a4157725a9 · Zeichen 2042–2516 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-108571 · Präparat HOS-093047
11
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine oral When possible, avoid chronic
13.4 g)/ Lamivudine solution 300 mg coadministration of Trizivir
with medicinal products
Lamivudine:
containing sorbitol or other
AUC 14%; 32%; 36% osmotic acting poly-alcohols
or monosaccharide alcohols
Cmax 28%; 52%, 55%. (e.g. xylitol, mannitol,
lactitol, maltitol). Consider
more frequent monitoring of
HIV-1 viral load when
chronic coadministration
cannot be avoided.
Riociguat/Abacavir Riociguat Riociguat dose may need to
be reduced. Consult the
In vitro, abacavir inhibits
riociguat prescribing
CYP1A1. Concomitant
information for dosing
administration of a single dose
recommendations.
of riociguat (0.5 mg) to HIV
patients receiving the
combination of
abacavir/dolutegravir/lamivudine
(600 mg/50 mg/300 mg once
daily) led to an approximately
three-fold higher riociguat
AUC(0-∞) when compared to
historical riociguat AUC(0-∞)
reported in healthy subjects.
Abbreviations: = Increase; =decrease; = no significant change; AUC=area under the
concentration versus time curve; Cmax=maximum observed concentration; CL/F=apparent oral
clearance
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) riociguat (HOS-086293) dolutegravir (HOS-089992) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage c4b1bb4a035cf3db319c881110ad4d95c1fe80a0464010149efaf1c0e709d897 · Zeichen 13071–15827 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26
HOS-108940 · Präparat HOS-093083
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of
contraception must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after
levothyroxine. starting and/or ending
lopinavir/ritonavir treatment.
Vasodilating agents
25
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should
AUC: ↑ 5-fold be closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of co-administration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) methadone (HOS-086198) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61
HOS-109024 · Präparat HOS-093083
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone (TSH)
reported indicating a potential should be monitored in patients
interaction between ritonavir treated with levothyroxine at least the
containing products and first month after starting and/or
levothyroxine. ending lopinavir/ritonavir treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with bosentan.
concentrations may decrease due When Kaletra is administered
to CYP3A4 induction by concomitantly with bosentan, the
bosentan. efficacy of the HIV therapy should
be monitored and patients should be
Bosentan: closely observed for bosentan
AUC: ↑ 5-fold toxicity, especially during the first
Cmax: ↑ 6-fold week of co-administration.
Initially, bosentan Cmin: ↑ by
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and P-gp with Kaletra is not recommended
inhibition by lopinavir/ritonavir. (see section 4.4 and refer to riociguat
SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 65f5a6f4d7302840533b08e744ce8d52c7c6cce98bf349aa71cfb302b25446dd · Zeichen 59068–61276 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97
HOS-109102 · Präparat HOS-093083
96
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after starting
levothyroxine. and/or ending lopinavir/ritonavir
treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should be
AUC: ↑ 5-fold closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of coadministration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage eb717f7573e257a0db9660c2692fa6be3f81b8ac5b4c1043b1f49219b74ffa31 · Zeichen 58967–62731 im Abschnitt
Gegenanzeigen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3–4
HOS-111244 · Präparat HOS-093485
3
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such
as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage b8f0aac665f326412e067f57e933b3248c7ecdadae6acd18e535a8414816663f · Zeichen 1532–1744 im Abschnitt
Gegenanzeigen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 18
HOS-111294 · Präparat HOS-093485
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such
as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 17c45f56c7062bdd9c33e8d92f489a98c3c29be4dc43c5d115abde508fcb57cc · Zeichen 1535–1744 im Abschnitt
Gegenanzeigen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 33
HOS-111332 · Präparat HOS-093485
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such
as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 17c45f56c7062bdd9c33e8d92f489a98c3c29be4dc43c5d115abde508fcb57cc · Zeichen 1534–1743 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-111262 · Präparat HOS-093485
Riociguat
Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors
were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
tadalafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 283ab2f7e84ff964b3367f26fcbe301129f8087a4a6a929ed88ee849f441717c · Zeichen 5712–6160 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-111304 · Präparat HOS-093485
Riociguat
Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors
were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
tadalafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 283ab2f7e84ff964b3367f26fcbe301129f8087a4a6a929ed88ee849f441717c · Zeichen 5659–6107 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 36
HOS-111344 · Präparat HOS-093485
Riociguat
Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors
were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
tadalafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 283ab2f7e84ff964b3367f26fcbe301129f8087a4a6a929ed88ee849f441717c · Zeichen 5715–6163 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.